Rapid Discovery of Potent anti-PD-L1 Antibodies Enabled by Single Plasma B Cell Cloning on the Beacon Platform and Epitope Binning with the Carterra LSA

Presented by Dr. Shrieen Khan, Senior Director of Biologics at ChemPartner


  • Antibody discovery in weeks versus years
  • Isolate, culture, and assay tens of thousands of single cells with the Beacon platform
  • Survey the epitope landscape of your antibody panel at the earliest stages of discovery with the Carterra LSA

PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its receptor, PD-1, have shown significant clinical benefit in some patients with PD-L1 expressing tumors. Hence, there is great interest in generating therapeutic antibodies against these targets to counteract the immune suppression mechanism that tumors rely on for survival.

Epitope binning studies on the Carterra LSA revealed that hybridoma antibodies covered more diverse epitope regions but potency in functional assays was weaker across all bins while B Cell Cloning antibodies were concentrated in fewer epitope bins that represented greater potency.

Our data show that plasma B cells secreting functional antibody candidates can be rapidly identified on the Beacon compared to several months for a hybridoma campaign and screening those antibodies for epitope specificity and affinity can be completed in just days on the Carterra LSA, thus substantially accelerating the antibody discovery process.

Keep watching…

Assay Platforms for PROTAC in Drug Discovery and Beyond

Assay Platforms for PROTAC in Drug Discovery and Beyond

Presented by Yuzhou Xu, Senior Director of Biology and Pharmacology at ChemPartner. Abstract: Discover a groundbreaking webinar delving into the in vitro assays for proteolysis targeting chimera (PROTAC). PROTACs are being developed more and more for many kinds of...

EEG Analysis and Animal Behavior in CNS Drug Development

EEG Analysis and Animal Behavior in CNS Drug Development

Presented by Ruiben Feng, PhD, Executive Director, Neurobiology and Neuropharmacology at Shanghai ChemPartner. Abstract: EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and...


1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203


Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000